These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21112627)

  • 1. Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.
    Erikçi E; Gursel M; Gürsel I
    Biomaterials; 2011 Feb; 32(6):1715-23. PubMed ID: 21112627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
    Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
    J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
    Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
    Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice.
    Zhu FG; Kandimalla ER; Yu D; Tang JX; Agrawal S
    Int Immunopharmacol; 2004 Jul; 4(7):851-62. PubMed ID: 15182725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
    Merlo A; Calcaterra C; Mènard S; Balsari A
    J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the type of liposome involving cytokine production induced by non-CpG Lipoplex in macrophages.
    Yasuda S; Yoshida H; Nishikawa M; Takakura Y
    Mol Pharm; 2010 Apr; 7(2):533-42. PubMed ID: 20047296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
    Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
    Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
    Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
    J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligodeoxynucleotides induce expression of proinflammatory cytokines and chemokines in astrocytes: the role of c-Jun N-terminal kinase in CpG ODN-mediated NF-kappaB activation.
    Lee S; Hong J; Choi SY; Oh SB; Park K; Kim JS; Karin M; Lee SJ
    J Neuroimmunol; 2004 Aug; 153(1-2):50-63. PubMed ID: 15265663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
    Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
    Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to influenza A virus infection by antigen-conjugated CpG oligonucleotides, a novel antigen-specific immunomodulator.
    Hayashi M; Satou E; Ueki R; Yano M; Miyano-Kurosaki N; Fujii M; Takaku H
    Biochem Biophys Res Commun; 2005 Apr; 329(1):230-6. PubMed ID: 15721298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.